Malaria is a major public health burden throughout the world. Resistance to the antimalarial
drugs has increased the mortality and morbidity rate that is achieved so far through the …

Plasmodium falciparum resistance to chloroquine, the former gold standard antimalarial
drug, is mediated primarily by mutant forms of the chloroquine resistance transporter …

Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the
artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum …

The use of artemisinin-based combination therapies (ACTs), which combine an artemisinin
derivative with a partner drug, in the treatment of uncomplicated malaria has largely been …

Resistance to antimalarial drugs has often threatened malaria elimination efforts and
historically has led to the short-term resurgence of malaria incidences and deaths. With …

Chloroquine (CQ) resistance (CQR) in Plasmodium falciparum originated from at least six
foci in South America, Asia, and Oceania. Malaria parasites from these locations exhibit …

The prevention and management of malaria is primarily based on the use of drugs. Clinical
trials have however revealed that between individuals there is large variability in the …

Mutant forms of the Plasmodium falciparum transporter PfCRT constitute the key determinant
of parasite resistance to chloroquine (CQ), the former first-line antimalarial, and are …

ABSTRACT The involvement of Pfmdr1 (Plasmodium falciparum multidrug resistance 1)
polymorphisms in antimalarial drug resistance is still debated. Here, we evaluate the …

Plasmodium falciparum response mechanisms to the major artemisinin-based combination
therapies (ACTs) are largely unknown. Multidrug-resistance protein (MRP)–like adenosine …